Burning Rock Biotech (BNR) Projected to Post Earnings on Tuesday

Burning Rock Biotech (NASDAQ:BNR) is expected to release its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($2.2875) per share and revenue of $19.20 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 12, 2026 at 7:00 AM ET.

Burning Rock Biotech (NASDAQ:BNR) last released its earnings results on Saturday, February 14th. The company reported ($0.21) earnings per share for the quarter. Burning Rock Biotech had a negative net margin of 10.27% and a negative return on equity of 9.98%. The firm had revenue of $18.05 million for the quarter.

Burning Rock Biotech Trading Down 11.6%

Shares of Burning Rock Biotech stock opened at $16.36 on Friday. Burning Rock Biotech has a 1-year low of $2.18 and a 1-year high of $41.72. The business has a 50-day moving average price of $27.03 and a two-hundred day moving average price of $19.25. The company has a market cap of $176.03 million, a P/E ratio of -20.71 and a beta of 1.35.

Hedge Funds Weigh In On Burning Rock Biotech

A hedge fund recently bought a new stake in Burning Rock Biotech stock. Marshall Wace LLP purchased a new stake in Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 10,903 shares of the company’s stock, valued at approximately $220,000. Marshall Wace LLP owned 0.10% of Burning Rock Biotech at the end of the most recent quarter. 30.03% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Burning Rock Biotech from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.